dyne-tx.com valid

Automatically discovered from public files. Ownership management is optional. Inclusion does not imply endorsement or publisher participation.

Manage this listing — optional · Visit publisher ↗

Claim my listing on Agent Web Map for dyne-tx.com:
1. POST https://agentwebmap.com/v1/sites/dyne-tx.com/claims and keep claim_id and claim_secret private.
2. Publish the proof: add the line "AgentWebMap ownership: <token>" (token from step 1) to https://dyne-tx.com/llms.txt, or use the DNS, meta-tag or well-known method the response describes.
3. POST https://agentwebmap.com/v1/sites/dyne-tx.com/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/dyne-tx.com).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verify

Corrections or removal requests: contact the directory. Ownership management is optional.

Dyne Therapeutics

Dyne Therapeutics, Inc. (Nasdaq: DYN) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, developing targeted therapeutics for genetically driven neuromuscular diseases. Dyne's proprietary FORCE™ platform conjugates an antigen-binding fragment (Fab) that binds transferrin receptor 1 (TfR1) to a therapeutic payload — such as an antisense oligonucleotide (ASO), phosphorodiamidate morpholino oligomer (PMO), siRNA or biologic — to enable delivery to muscle and the cent

Their llms.txt

The beginning of the file, from our validated copy saved 2026-10-20T22:57:23.324Z. Cached copy · Source on dyne-tx.com

# Dyne Therapeutics

> Dyne Therapeutics, Inc. (Nasdaq: DYN) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, developing targeted therapeutics for genetically driven neuromuscular diseases. Dyne's proprietary FORCE™ platform conjugates an antigen-binding fragment (Fab) that binds transferrin receptor 1 (TfR1) to a therapeutic payload — such as an antisense oligonucleotide (ASO), phosphorodiamidate morpholino oligomer (PMO), siRNA or biologic — to enable delivery to muscle and the central nervous system (CNS) and address the root cause of disease. Dyne is advancing clinical programs in Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), and preclinical programs in Pompe disease and additional DMD exon-skipping targets.

Last updated: August 24, 2026. Consolidated content of the pages listed below, in a single file: https://www.dyne-tx.com/llms-full.txt

Key facts:

- Legal name: Dyne Therapeutics, Inc.
- Founded: 2017
- Headquarters: 1560 Trapelo Road, Waltham, MA 02451, USA
- Phone: +1 781-786-8230
- Publicly traded: Nasdaq Global Select Market, ticker DYN; IPO September 16, 2020; incorporated in Delaware
- Employees: approximately 289 (as of August 2026)
- Stage: clinical-stage biotechnology
- Core technology: FORCE™ platform (Fab–linker–payload conjugate targeting TfR1)
- Therapeutic areas: DMD, DM1, FSHD, Pompe disease
- Lead candidates: zeleciment rostudirsen (z-rostudirsen, DYNE-251) for DMD exon 51; zeleciment basivarsen (z-basivarsen, DYNE-101) for DM1
- Regulatory status: BLA for z-rostudirsen accepted by the FDA with Priority Review; PDUFA target action date January 21, 2027; potential U.S. launch expected in the first quarter of 2027 if approval is received on the anticipated timeline
- General inquiries: info@dyne-tx.com | Partnerships: partnerships@dyne-tx.com | Patient advocacy: patientadvocacy@dyne-tx.com | Investors and media: ir@dyne-tx.com | Clinical trials: clinicaltrials@dyne-tx.com | Possible side effects of an investigational therapeutic: MedSafety@Dyne-tx.com

Diseases Dyne is targeting:

- Duchenne muscular dystrophy (DMD): rare, X-linked, progressive neuromuscular disorder caused by mutations in the DMD gene leading to absent or nearly undetectable dystrophin. Affects approximately 12,000 people in the U.S. and 16,000 in Europe. Onset typically between 3 and 5 years of age.
- Myotonic dystrophy type 1 (DM1): rare, progressive genetic neuromuscular disease caused by mutations in the DMPK gene that cause widespread disruption of RNA splicing (spliceopathy). Affects approximately 40,000 people in the U.S. and 55,000 in Europe. No approved disease-modifying treatments.
- Facioscapulohumeral muscular dystrophy (FSHD): rare, progressive genetic disease caused by aberrant DUX4 expression in muscle. Affects approximately 15,000–40,000 people in the U.S. and 20,000–50,000 in Europe. No approved disease-modifying treatments.
- Pompe d
…

Help agents understand your site

Optionally manage your description, publish terms for agents, review file health, measured discovery requests, publisher clicks and score history. Confirm domain control in your browser using a fresh token in your llms.txt, DNS, meta tag or well-known file. No backlink is required.

Manage this listing → · Agent and API instructions

Machine-readable: GET /v1/resolve?q=dyne-tx.com · GET /v1/domain/dyne-tx.com · this page as Accept: application/json or text/markdown · MCP lookup_domain